No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.
aristolochic acid
drug safety
hepatocellular carcinoma
retrospective study
urinary cancer
Journal
Chinese journal of integrative medicine
ISSN: 1993-0402
Titre abrégé: Chin J Integr Med
Pays: China
ID NLM: 101181180
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
accepted:
17
07
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
aheadofprint
Résumé
To assess the risk of aristolochic acid (AA)-associated cancer in patients with AA nephropathy (AAN). A retrospective study was conducted on patients diagnosed with AAN at Peking University First Hospital from January 1997 to December 2014. Long-term surveillance and follow-up data were analyzed to investigate the influence of different factors on the prevalence of cancer. The primary endpoint was the incidence of liver cancer, and the secondary endpoint was the incidence of urinary cancer during 1 year after taking AA-containing medication to 2014. A total of 337 patients diagnosed with AAN were included in this study. From the initiation of taking AA to the termination of follow-up, 39 patients were diagnosed with cancer. No cases of liver cancer were observed throughout the entire follow-up period, with urinary cancer being the predominant type (34/39, 87.17%). Logistic regression analysis showed that age, follow-up period, and diabetes were potential risk factors, however, the dosage of the drug was not significantly associated with urinary cancer. No cases of liver cancer were observed at the end of follow-up. However, a high prevalence of urinary cancer was observed in AAN patients. Establishing a direct causality between AA and HCC is challenging.
Identifiants
pubmed: 37943487
doi: 10.1007/s11655-023-3560-0
pii: 10.1007/s11655-023-3560-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387–391.
doi: 10.1016/0140-6736(93)92984-2
pubmed: 8094166
Boot A, Jiang N, Rozen SG. Toward clinical understanding of aristolochic acid upper-tract urothelial carcinoma. Theranostics 2020;10:5578–5580.
doi: 10.7150/thno.46489
pubmed: 32373232
pmcid: 7196294
Lu H, Liang Y, Guan B, Shi Y, Gong Y, Li J, et al. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics 2020;10:4323–4333.
doi: 10.7150/thno.43251
pubmed: 32292497
pmcid: 7150494
Nault JC, Letouzé E. Mutational processes in hepatocellular carcinoma: the story of aristolochic acid. Semin Liver Dis 2019;39:334–340.
doi: 10.1055/s-0039-1685516
pubmed: 31041788
Bastek H, Zubel T, Stemmer K, Mangerich A, Beneke S, Dietrich DR. Comparison of aristolochic acid I derived DNA adduct levels in human renal toxicity models. Toxicology 2019;420:29–38.
doi: 10.1016/j.tox.2019.03.013
pubmed: 30940547
Jadot I, Declèves AE, Nortier J, Caron N. An integrated view of aristolochic acid nephropathy: update of the literature. Int J Mol Sci 2017;18:297.
doi: 10.3390/ijms18020297
pubmed: 28146082
pmcid: 5343833
Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, et al. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 2014;135:502–507.
doi: 10.1002/ijc.28681
pubmed: 24921086
Anger EE, Yu F, Li J. Aristolochic acid-induced nephrotoxicity: molecular mechanisms and potential protective approaches. Int J Mol Sci 2020;21:1157.
doi: 10.3390/ijms21031157
pubmed: 32050524
pmcid: 7043226
Zhao H, Jiang N, Han Y, Yang M, Gao P, Xiong X, et al. Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G
doi: 10.1096/fj.202000949R
pubmed: 32706145
Pu XY, Shen JY, Deng ZP, Zhang ZA. Oral exposure to aristolochic acid I induces gastric histological lesions with non-specific renal injury in rat. Exp Toxicol Pathol 2016;68:315–320.
doi: 10.1016/j.etp.2016.03.003
pubmed: 27019954
Wang L, Li C, Tian J, Liu J, Zhao Y, Yi Y, et al. Genome-wide transcriptional analysis of aristolochia manshuriensis induced gastric carcinoma. Pharm Biol 2020;58:98–106.
doi: 10.1080/13880209.2019.1710219
pubmed: 31957525
pmcid: 7006638
Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 2017;9:eaan6446.
doi: 10.1126/scitranslmed.aan6446
pubmed: 29046434
Chen CJ, Yang YH, Lin MH, Lee CP, Tsan YT, Lai MN, et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Int J Cancer 2018;143:1578–1587.
doi: 10.1002/ijc.31544
pubmed: 29667191
Chen CJ, Yang YH, Lin MH, Lee CP, Tsan YT, Lai MN, et al. Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection. Cancer Epidemiol Biomarkers Prev 2019;28:1876–1883.
doi: 10.1158/1055-9965.EPI-19-0023
pubmed: 31409611
Lu ZN, Luo Q, Zhao LN, Shi Y, Wang N, Wang L, et al. The mutational features of aristolochic acid-induced mouse and human liver cancers. Hepatology 2020;71:929–942.
doi: 10.1002/hep.30863
pubmed: 31692012
Yang L, Su T, Li XM, Wang X, Cai SQ, Meng LQ, et al. Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant 2012;27:292–298.
doi: 10.1093/ndt/gfr291
pubmed: 21719716
Ministry of Health of the People’s Republic of China. Updated standards for the diagnosis and treatment of primary liver cancer. Chin J Hepatol (Chin) 2020;33:112–128.
Na YQ, Sun G, eds. Chinese diagnosis and treatment of urological diseases guide. Beijing: People’s Medical Publishing House; 2009:3–115.
Ban TH, Min JW, Seo C, Kim DR, Lee YH, Chung BH, et al. Update of aristolochic acid nephropathy in Korea. Kor J Intern Med 2018;33:961–969.
doi: 10.3904/kjim.2016.288
Shan H, Tian W, Hong Y, Xu B, Wang C, Yu B, et al. Clinicopathologic characteristics and prognosis of upper tract urothelial carcinoma complicated with aristolochic acid nephropathy after radical nephroureterectomy. BMC Complement Med Ther 2020;20:166.
doi: 10.1186/s12906-020-2861-5
pubmed: 32493345
pmcid: 7268428
Zhang HM, Zhao XH, Sun ZH, Li GC, Liu GC, Sun LR, et al. Recognition of the toxicity of aristolochic acid. J Clin Pharm Ther 2019;44:157–162.
doi: 10.1111/jcpt.12789
pubmed: 30548302
Hoang ML, Chen CH, Chen PC, Roberts NJ, Dickman KG, Yun BH, et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2016;25:1600–1608.
doi: 10.1158/1055-9965.EPI-16-0219
pubmed: 27555084
pmcid: 5533284
Hu X, Shen J, Pu X, Zheng N, Deng Z, Zhang Z, et al. Urinary time- or dose-dependent metabolic biomarkers of aristolochic acid-induced nephrotoxicity in rats. Toxicol Sci 2017;156:123–132.
pubmed: 28115647
Fang ZE, Guo Y, Wang Z, He T, Wang J, Bai Z, et al. Asari Radix et Rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: a retrospective cohort study. Chin Herb Med 2022;14:470–475.
doi: 10.1016/j.chmed.2022.01.004
pubmed: 36117998
pmcid: 9476760
Xiong G, Yao L, Hong P, Yang L, Ci W, Liu L, et al. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer Manag Res 2018;10:6627–6639.
doi: 10.2147/CMAR.S178554
pubmed: 30584358
pmcid: 6284533
Sun M, Zhang J, Zheng C, Liu Y, Lin F, Xu F, et al. Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. Renal Failure 2015;37:209–213.
doi: 10.3109/0886022X.2014.990347
pubmed: 25540870
Bara TJr, Gurzu S, Sugimura H, Bara T, Beleaua MA, Jung I. A systematic review of the possible carcinogenic role of the aristolochic acid. Rom J Morphol Embryol 2017;58:41–44.
pubmed: 28523296